Loes Kooreman

2.5k total citations
52 papers, 558 citations indexed

About

Loes Kooreman is a scholar working on Cancer Research, Oncology and Surgery. According to data from OpenAlex, Loes Kooreman has authored 52 papers receiving a total of 558 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Cancer Research, 14 papers in Oncology and 13 papers in Surgery. Recurrent topics in Loes Kooreman's work include Breast Cancer Treatment Studies (19 papers), Endometrial and Cervical Cancer Treatments (13 papers) and Ovarian cancer diagnosis and treatment (11 papers). Loes Kooreman is often cited by papers focused on Breast Cancer Treatment Studies (19 papers), Endometrial and Cervical Cancer Treatments (13 papers) and Ovarian cancer diagnosis and treatment (11 papers). Loes Kooreman collaborates with scholars based in Netherlands, United States and Germany. Loes Kooreman's co-authors include Marjolein L. Smidt, Marc B. I. Lobbes, Thiemo J. A. van Nijnatten, Roy F.P.M. Kruitwagen, Joachim E. Wildberger, B. Goorts, Kristien Keymeulen, Sabine Siesling, Janine M. Simons and Sanaz Samiei and has published in prestigious journals such as SHILAP Revista de lepidopterología, Cancer and Annals of Surgery.

In The Last Decade

Loes Kooreman

45 papers receiving 554 citations

Peers

Countries citing papers authored by Loes Kooreman

Since Specialization

Citations

This map shows the geographic impact of Loes Kooreman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Loes Kooreman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Loes Kooreman more than expected).

Fields of papers citing papers by Loes Kooreman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Loes Kooreman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Loes Kooreman. The network helps show where Loes Kooreman may publish in the future.

Co-authorship network of co-authors of Loes Kooreman

This figure shows the co-authorship network connecting the top 25 collaborators of Loes Kooreman. A scholar is included among the top collaborators of Loes Kooreman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Loes Kooreman. Loes Kooreman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pre-existing infiltration with T cells and CD14+ myeloid cells is associated with treatment response to imiquimod in primary and recurrent vulvar high-grade squamous intraepithelial lesions 2025 ·Journal for ImmunoTherapy of Cancer ·(unknown), Peggy J. de Vos van Steenwijk, Loes Kooreman, Sigrid Regauer, (unknown), Ruud L.M. Bekkers, Sjoerd H. van der Burg, Gerda Trutnovsky, Edith M.G. van Esch	0
2	Overall survival of patients with de Novo HER2-positive metastatic breast cancer in the Netherlands from 2008 to 2017: A population-based cohort study of systemically treated patients 2025 ·European Journal of Cancer ·(unknown), (unknown), Thiemo J. A. van Nijnatten, Sanne Engelen, Jolien Tol, Loes Kooreman, Marie-Jeanne T. F. D. Vrancken Peeters, Sabine Siesling, Adri C. Voogd, Vivianne C. G. Tjan‐Heijnen, Sandra M. E. Geurts	1
3	The prognostic potential of molecular subtypes including estrogen receptor status in endometrioid ovarian cancer 2025 ·Gynecologic Oncology ·(unknown), (unknown), Floris H. Groenendijk, (unknown), Gerrit K. Hooijer, Willemien J. van Driel, Alicia León‐Castillo, Christianne Lok, Loes Kooreman, (unknown), (unknown), Roy J. Reinten, (unknown), (unknown), Ronald van Marion, Frederike Dijk, Marc J. van de Vijver, Constantijne H. Mom, Mignon D J M van Gent	0
4	Pilot Data Suggest That Obesity and Presence of Malignancy Are Associated with Altered Immune Cell Infiltration in Endometrial Biopsies 2024 ·Journal of Clinical Medicine ·(unknown), (unknown), (unknown), Loes Kooreman, Bert Delvoux, Andrea Romano, Henrica M.J. Werner	0
5	Does “One Size Fits All”? Rethinking FIGO Depth of Invasion Measurements in Vulvar Cancer 2024 ·International Journal of Gynecological Pathology ·Maaike C.G. Bleeker, Tjalling Bosse, Koen Van de Vijver, Joost Bart, Hugo M. Horlings, Trudy Jonges, Nicole C.M. Visser, Loes Kooreman, Johan Bulten, Patricia C. Ewing‐Graham	0
6	Functional estrogen receptor signal transduction pathway activity and antihormonal therapy response in low‐grade ovarian carcinoma 2023 ·Cancer ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Christianne Lok, Joanne A. de Hullu, H.P.M. Smedts, M. Caroline Vos, Brenda Pijlman, Loes Kooreman, Johan Bulten, (unknown), Steven L. Bosch, Anja van de Stolpe, Sandrina Lambrechts, Ruud L.M. Bekkers, Jurgen M.J. Piek	4
7	Prediction of Primary Tumour and Axillary Lymph Node Response to Neoadjuvant Chemo(Targeted) Therapy with Dedicated Breast [18F]FDG PET/MRI in Breast Cancer 2023 ·Cancers ·(unknown), Thiemo J. A. van Nijnatten, B. Goorts, Loes Kooreman, (unknown), (unknown), Maaike de Boer, Kristien Keymeulen, Joachim E. Wildberger, Felix M. Mottaghy, Marc B. I. Lobbes, Marjolein L. Smidt	6
8	The clinical importance of the host anti-tumour reaction patterns in regional tumour draining lymph nodes in patients with locally advanced resectable gastric cancer: a systematic review and meta-analysis 2023 ·Gastric Cancer ·(unknown), (unknown), Sander M. J. van Kuijk, (unknown), Loes Kooreman, (unknown), Derek Magee, Henry C. Woodruff, Heike I. Grabsch	1
9	The prognostic value of the histological shape of tumor negative sentinel nodes in breast cancer 2023 ·Frontiers in Immunology ·Loes Kooreman, (unknown), Sander M. J. van Kuijk, Axel zur Hausen, Marjolein L. Smidt, Heike I. Grabsch	1
10	Clinical value of contralateral breast cancers detected by pre-operative MRI in patients diagnosed with DCIS: a population-based cohort study 2022 ·European Radiology ·(unknown), Sandra M. E. Geurts, Loes Kooreman, Luciën E. M. Duijm, Sanne Engelen, (unknown), Ernest J. T. Luiten, (unknown), Adri C. Voogd, Vivianne C. G. Tjan‐Heijnen	3
11	An in vitro model to monitor natural killer cell effector functions against breast cancer cells derived from human tumor tissue 2022 ·Methods in cell biology ·(unknown), (unknown), Loes Kooreman, Gerard M.J. Bos, Lotte Wieten	1
12	The percentage of residual DCIS in patients diagnosed with primary invasive breast cancer treated with neoadjuvant systemic therapy: A nationwide retrospective study 2021 ·European Journal of Surgical Oncology ·(unknown), Kristien Keymeulen, Loes Kooreman, Sander M. J. van Kuijk, Sabine Siesling, Marjolein L. Smidt, Thiemo J. A. van Nijnatten	3
13	Pharmacological inhibition of 17β-hydroxysteroid dehydrogenase impairs human endometrial cancer growth in an orthotopic xenograft mouse model 2021 ·Cancer Letters ·Sofia Xanthoulea, (unknown), Niina Saarinen, Bert Delvoux, Loes Kooreman, Pasi Koskimies, Merja R. Häkkinen, Seppo Auriola, (unknown), (unknown), Frank Verhaegen, Natasja G. Lieuwes, Florian Caiment, Roy F.P.M. Kruitwagen, Andrea Romano	7
14	Female adnexal tumors of probable Wolffian origin: morphological, immunohistochemical, and molecular analysis of 15 cases 2019 ·Modern Pathology ·Jennifer A. Bennett, Lauren L. Ritterhouse, Larissa V. Furtado, Ricardo R. Lastra, Anna Pesci, Jordan M. Newell, Eike Burandt, Loes Kooreman, Koen Van de Vijver, Thomas Krausz, Ana Félix, Gian Franco Zannoni, Robert H. Young, Esther Oliva	27
15	Prognostic factors for spontaneous regression of high-risk human papillomavirus-positive cervical intra-epithelial neoplasia grade 2 2019 ·International Journal of Gynecological Cancer ·Margot M. Koeneman, (unknown), Loes Kooreman, Björn Winkens, Roy F.P.M. Kruitwagen, (unknown)	15
16	Extracapsular extension in the positive sentinel lymph node: a marker of poor prognosis in cT1-2N0 breast cancer patients? 2019 ·Breast Cancer Research and Treatment ·(unknown), (unknown), Lori M. van Roozendaal, Sander M. J. van Kuijk, Loes Kooreman, Sabine Siesling, (unknown), Marjolein L. Smidt	7
17	Economic evaluation of an expert examiner and different ultrasound models in the diagnosis of ovarian cancer 2018 ·European Journal of Cancer ·Evelyne M. J. Meys, (unknown), Bram Ramaekers, Carmen D. Dirksen, Loes Kooreman, B.F.M. Slangen, Roy F.P.M. Kruitwagen, Toon Van Gorp	3
18	Development of an Image-Guided Orthotopic Xenograft Mouse Model of Endometrial Cancer with Controllable Estrogen Exposure 2018 ·International Journal of Molecular Sciences ·(unknown), Niina Saarinen, Bert Delvoux, Loes Kooreman, Pasi Koskimies, Camilla Krakstad, Kristine E. Fasmer, Ingfrid S. Haldorsen, (unknown), Merja R. Häkkinen, Seppo Auriola, Ludwig J. Dubois, Natasja G. Lieuwes, Frank Verhaegen, (unknown), Roy F.P.M. Kruitwagen, Sofia Xanthoulea, Andrea Romano	11
19	Hybrid 18F–FDG PET/MRI might improve locoregional staging of breast cancer patients prior to neoadjuvant chemotherapy 2017 ·European Journal of Nuclear Medicine and Molecular Imaging ·B. Goorts, Stefan Vöö, Thiemo J. A. van Nijnatten, Loes Kooreman, Maaike de Boer, Kristien Keymeulen, Romy Aarnoutse, Joachim E. Wildberger, Felix M. Mottaghy, Marc B. I. Lobbes, Marjolein L. Smidt	21
20	Staging procedures in patients with mucinous borderline tumors of the ovary do not reveal peritoneal or omental disease 2016 ·Gynecologic Oncology ·Koen De Decker, (unknown), Henk G. ter Brugge, Joost Bart, Leon F.A.G. Massuger, Marjolein Kleppe, Loes Kooreman, Roy F.P.M. Kruitwagen, Arnold‐Jan Kruse	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact